SLC5A2 and atrial fibrillation: SGLT2 inhibitors reduced AF risk (HR 0.68; 95% CI: 0.56–0.83; p = 0.0001) and cardiovascular mortality (HR 0.39; 95% CI: 0.27–0.56; p < 0.0001).